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Engineering Recombinant Orsay Virus Directly in the Metazoan Host
Caenorhabditis elegans
Hongbing Jiang, Carl J. Franz, David Wang
Departments of Molecular Microbiology and Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
ABSTRACT
The recent identification of Orsay virus, the first virus that is capable of naturally infecting Caenorhabditis elegans, provides a
unique opportunity to explore host-virus interaction studies in this invaluable model organism. A key feature of this system is
the robust genetic tractability of the host, C. elegans, which would ideally be complemented by the ability to genetically manipu-
late Orsay virus in parallel. To this end, we developed a plasmid-based reverse genetics system for Orsay virus by creating trans-
genic C. elegans strains harboring Orsay virus cDNAs. Both wild-type and mutant Orsay viruses, including a FLAG epitope-
tagged recombinant Orsay virus, were generated by use of the reverse genetics system. This is the first plasmid-based virus
reverse genetics system in the metazoan C. elegans. The Orsay virus reverse genetics we established will serve as a fundamental
tool in host-virus interaction studies in the model organism C. elegans.
IMPORTANCE
To date, Orsay virus is the first and the only identified virus capable of naturally infecting Caenorhabditis elegans. C. elegans is a
simple multicellular model organism that mimics many fundamental features of human biology and has been used to define
many biological properties conserved through evolution. Thus, the Orsay virus-C. elegans infection system provides a unique
opportunity to study host-virus interactions. In order to take maximal advantage of this system, the ability to genetically engi-
neer mutant forms of Orsay virus would be highly desirable. Most efforts to engineer viruses have been done with cultured cells.
Here we describe the creation of mutant viruses directly in the multicellular organism C. eleganswithout the use of cell culture.
We engineered a virus expressing a genetically tagged protein that could be detected in C. elegans. This provides proof of concept
for modifying Orsay virus, which will greatly facilitate studies in this experimental system.
Orsay virus, which was recently discovered in a wild Caeno-rhabditis elegans strain, is the only known virus capable of
naturally infecting the model organism C. elegans (1). Orsay virus
has a bipartite positive-sense RNA genome and is most closely
related to nodaviruses (1, 2). The Orsay virus RNA1 genome seg-
ment, which is 3.4 kb in length, encodes an RNA-dependent
RNA polymerase (RdRP), while the Orsay virus RNA2 genome
segment, which is2.5 kb, encodes the viral capsid protein and a
novel capsid-delta fusion protein of unknown function that is
expressed by a ribosomal frameshifting mechanism (3).
Asmany fundamental biological discoveries have beenmade in
the C. elegansmodel, the ability of Orsay virus to infect C. elegans
provides a unique and powerful experimental system to define
multiple aspects of host-virus interactions. Prior to the discovery
of Orsay virus, only limited studies with C. elegans using a Flock
House virus replicon (4), vesicular stomatitis virus infection of
primary nematode cells (5, 6), or artificial infection of C. elegans
by vaccinia virus (7) have been reported. Those studies defined
antiviral roles for the RNA interference (RNAi) pathway and
apoptosis genes in C. elegans. To date, analysis of Orsay virus in-
fection has confirmed a role for the RNAi pathway, and dicer-
related helicase 1 (drh-1) in particular, in antiviral defense in C.
elegans (8, 9). Additional efforts to define novel pathways of anti-
viral immunity usingOrsay virus will capitalize on the robust host
genetics available in C. elegans. As most viruses encode proteins
that antagonize host antiviral defenses, it would be ideal if the
Orsay virus genome could be manipulated to identify such pro-
teins. The Orsay-C. elegans system could also exploit another
unique property of C. elegans, its transparency, which could be
leveraged to directly visualize Orsay virus infection and spread in
vivo, provided a suitable reporter virus (e.g., fluorescently tagged)
could be created. Furthermore, the ability to genetically define a
function for the novel capsid-delta fusion protein would be en-
hanced by creatingmutant viruses that cannot express the capsid-
delta fusion protein. Thus, engineering Orsay virus would greatly
enhance studies in the Orsay-C. elegans infection system.
For many viruses, reverse genetics have been developed in or-
der to be able to create mutant viruses (10–15). Reverse genetics
systems for multiple nodaviruses, including Flock House virus,
Pariacoto virus, and a fish-infecting betanodavirus, have been de-
scribed previously (16–20). In these examples, a viral cDNA con-
struct driven by a T7 promoter is transfected into mammalian
cells that express a helper T7 polymerase. All of these systems rely
upon mammalian cell cultures for the generation of recombinant
virus. However, no cell culture system capable of propagating Or-
say virus has been identified, and therefore, an alternative ap-
proach is required to develop reverse genetics for Orsay virus.
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Foreign genes can be readily introduced and expressed in C.
elegans by methodologies such as microinjection or gene bom-
bardment (21–23). Foreign geneticmaterial is usually preserved as
an extrachromosomal DNA array and can be inherited by the next
generation in a semistable manner (23, 24). Addition of a pheno-
typic selection marker (either a fluorescent or a behavioral
marker) facilitates the maintenance of animals carrying the extra-
chromosomal arrays, or alternatively, the plasmids can be stably
integrated into the C. elegans genome by X-ray or gamma ray
irradiation (21). Using this approach, a transgenic Flock House
virus replicon system has been previously created for C. elegans
that supports Flock House virus RNA replication but not viral
capsid assembly or spread (4). This system has been used to iden-
tify a role for RNAi in antiviral defense in C. elegans (4, 25), for
transgenerational inheritance of small virus-derived RNAs (26),
and to identify suppressors of RNA silencing (27). More recently,
a transgenic system for generating recombinant Sindbis virus in
Drosophila was described (28), providing the first example of en-
gineering infectious virus particles in a metazoan host.
Here, we describe the first plasmid-based virus reverse genetics
system in C. elegans. By generating transgenic animals that stably
maintain plasmids encoding Orsay virus using standard nema-
tode manipulations, we bypassed the need for traditional cell cul-
ture. Viable virus production was demonstrated by de novo infec-
tion of C. elegans with viral filtrates produced from the transgenic
animals. In addition to recombinant wild-type Orsay virus, mu-
tant viruses carrying either multiple synonymous mutations or a
FLAG epitope tag fused to the Orsay alpha-delta fusion protein
were generated. This novel reverse genetics system provides a
route to engineer definedmutations in theOrsay genome that will
greatly facilitate studies of both the virus life cycle and its interac-
tions with the host.
MATERIALS AND METHODS
C. elegans strains. Laboratory Caenorhabditis elegans Bristol N2 strain
and the RNAi-deficient mutant rde-1 strain (WM27) were maintained by
feeding with Escherichia coli bacterial strain OP50 at 20°C on nematode
growth medium (NGM) plates (29). Serial passage of both C. elegans N2
and the rde-1 strain was done by transferring 1 cm2 of agar with mixed-
stage animals onto a fresh OP50-seeded NGM plate.
Plasmid construction. (i) pHIP_RNA1 cloning. The complete Orsay
virus RNA1 segment was cloned into plasmid pPD49.83 driven by a C.
elegans heat shock promoter (30). First, the hepatitis D virus (HDV) ri-
bozyme sequence (31) was introduced at the 3= end by step extension PCR
with three overlapping primers (Table 1; see also Fig. S1 in the supple-
mental material). A multistep cloning strategy was used to insert this
fragment into plasmid pPD49.83 as follows. A partial sequence of the heat
shock promoter along with the NsiI site was introduced during step ex-
tension PCR amplification and was then cloned into a Topo-TA cloning
vector (Invitrogen). The resulting Topo-RNA1 was digested by NsiI and
XmaI. Two fragments were generated from the Topo-RNA1 genome be-
sides the vector due to the presence of a secondNsiI site in the Orsay virus
RNA1 genome. One of the digested fragments flanked by NsiI and XmaI
was subcloned into pPD49.83 vector, which was also digested by NsiI and
XmaI restriction enzymes. The resulting intermediate plasmids were fur-
ther singly digested by NsiI and ligated to the second delta-NsiI fragment
digested from the aforementioned Topo-RNA1. The orientation of inser-
tion was checked by restriction enzyme digestion and verified by Sanger
sequencing. The final plasmid construct was designated pHIP_RNA1.
(ii) pHIP_RNA2cloning.HDVribozymewas introduced at the 3= end
of theOrsay virus RNA2 genomeby step extensionPCR.A strategy similar
to that for cloning Orsay virus RNA1 was implemented (Table 1; see also
Fig. S1 in the supplemental material). Briefly, part of the heat shock pro-
moter sequence along with the PstI site was introduced into the RNA2
genome by PCR amplification and was then cloned into the Topo-TA
vector (Invitrogen). The resulting Topo-RNA2 was digested by PstI and
BamHI. The pPD49.83 vector was also digested by the two restriction
enzymes PstI and BamHI, and a 335-bp fragment was removed from the
vector, as there are two PstI sites on the vector sequence. Orsay virus
RNA2 with HDV ribozyme and partial promoter sequence digested from
Topo-RNA2 was ligated with pPD49.83 without the 335-bp fragment.
The resulting plasmids were then singly digested by PstI, and the 335-bp
fragment was then inserted. The orientation of insertion was checked by
restriction enzyme digestion and verified by Sanger sequencing. The final
plasmid construct was designated pHIP_RNA2.
(iii) pHIP_RNA1MUT cloning. For generation of a genetic marker in
the Orsay virus genome, a fragment of Orsay virus RNA1 was PCR am-
plified with a forward primer, RNA1muX, which has the designated mu-
tations (C, C, and T), and a reverse primer, HIPR1R. The PCR product
was further digested with XhoI and XmaI and then ligated into
pHIP_RNA1 digested with the same two restriction enzymes. The final
plasmid was sequence confirmed by Sanger sequencing and was desig-
nated pHIP_RNA1MUT.
(iv) pHIP_RNA2FLAG cloning.A sequence encoding a short peptide
linker (SGAAA) followed by the FLAGpeptide (DYKDDDDK)was intro-
duced into the 3= end of the alpha-delta coding region of Orsay virus
RNA2 by overlapping PCR. Briefly, a C-terminal 1-kb fragment of the
Orsay virus RNA2 alpha-delta open reading frame (ORF) was generated
by PCR with a forward primer, R2MF, and a reverse primer, R2MR. A 3=















a The mutated nucleotides are in bold type.
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fragment of pHIP_RNA2 was generated by PCR amplification with a for-
ward primer, R2FLAGF, which bears the FLAG sequence, and a reverse
primer, HIPR2R. The two fragments were then annealed together and
amplified by primers R2MF and HIPR2R. The resulting fragment was
digested by MfeI and BamHI and then cloned into the pHIP_RNA2 plas-
mid, which was digested by the same two restriction enzymes. The result-
ing plasmid is designated pHIP_RNA2FLAG. All primer sequences used
in this study are listed in Table 1.
Microinjection and transgenic lines. One day prior to the microin-
jection experiment, L4 C. elegans larvae were picked onto a fresh OP50-
seeded NGM plate. For microinjection, two viral cDNA-carrying plas-
mids (pHIP_RNA1 and pHIP_RNA2 or mutant forms of these plasmids)
were mixed with the comicroinjection marker plasmid pRF4 (rol-6) (32)
at final concentrations of 50 ng/l, 50 ng/l, and 120 ng/l, respectively.
C. elegans N2 or rde-1 young adults were injected by using a microinjec-
tion system (Zeiss). Sets of three microinjected animals were placed on
OP50-seeded 6-cm NGM plates and maintained at 20°C. F1 animals dis-
playing a roller phenotype were individually transferred onto new OP50-
seeded 6-cmNGMplates 3 to 5 days after injection. F1 plates that produce
F2 roller animals were considered to contain a stable transgenic line. The
stable transgenic lines were maintained and passaged by picking 5 roller
transgenic progeny animals each time onto a new OP50-seeded 6-cm
NGM plate.
Heat induction and transgenic virus filtrate preparation. Heat in-
duction was performed on stable transgenic animals. Five F2 transgenic
roller animals were transferred to a new OP50-seeded 6-cm NGM plate
and maintained for 5 days at 20°C to generate a mixed population. For
heat induction, animals were incubated at 33°C for 2 h and then at 23°C
for 2 days. Animals on each 6-cm NGM plate were harvested by washing
off the plates with 1ml ofM9 buffer, pelleted by spinning at 3,000 rpm for
1min, and concentrated to 0.5ml ofM9 buffer. The concentrated animals
were resuspended and transferred to a homogenizing tube. Animals were
mixed with 0.5 ml of 1.0-mm silicon beads (zirconia/silica) and then
homogenized by 2 cycles of shaking at 6,000 rpm for 1 min in a tissue
homogenizer (MagNALyzer; Roche) and cooling on ice for 2 min. The
resulting homogenate was centrifuged at maximum speed with a
benchtop Eppendorf centrifuge for 5 min. The supernatant was col-
lected and filtered through a 0.22-m filter (Millipore) and stored at
80°C.
Virus infection and real-time qRT-PCR quantification of virus rep-
lication. To quantify Orsay virus production from transgenic C. elegans,
we developed a standard 6-well format infection. Briefly, a synchronized
population of C. elegans embryos was generated by bleaching, which kills
all of the adult animals. Five hundred C. elegans embryos were added per
well of a 6-well plate seeded with a 20-l lawn of OP50 bacteria. Sixteen
hours later, 20 l of transgenic Orsay virus filtrate was added to the bac-
terial lawn of each well. Infected C. elegans animals were harvested 3 days
after infection. Animals werewashed off the plates using 1ml ofM9 buffer
(3 g of KH2PO4, 6 g of Na2HPO4, 5 g of NaCl, 1ml of 1MMgSO4, H2O to
1 liter) and then pelleted by centrifugation at 3,000 rpm for 2 min with a
benchtopEppendorf centrifuge.M9bufferwas removed by pipetting. The
C. elegans pellet was resuspended with 350 l of TRIzol (Invitrogen) and
frozen in liquid nitrogen. RNA extraction and DNase treatment in the
middle of RNA extraction were performed using a Zymo Direct-zol RNA
extraction kit (ZymoResearch) by following themanufacturer’s protocol.
RNA was eluted in 30 l of RNase- and DNase-free water. One-step real-
time quantitative reverse transcription-PCR (qRT-PCR) was performed
with Orsay virus RNA1 or RNA2 probe in a 1:100 dilution of viral RNA as
described previously (3).
Microinject young adult C. elegans
Pick out transgenic C. elegans 







De novo infection on naïve C. elegans
qRT-PCR Western blotIFA
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FIG 1 Design and work flow of Orsay virus reverse genetics. (A) Design of the
Orsay virus reverse genetics constructs. Orsay virus cDNAs for the entire
RNA1 and RNA2 genome segments were each cloned into a heat-inducible
promoter (pHIP)-driven plasmid and juxtaposed at the 3= end to the self-
cleaving hepatitis D virus ribozyme (RZ) to generate pHIP_RNA1 and
pHIP_RNA2, respectively. Arrows indicate the transcription start site and the
ribozyme cleavage site. (B) Experimental strategy of the Orsay virus reverse
genetics. Recombinant viral plasmids were microinjected into C. elegans to
establish transgenic animals. Viruses were then produced from transgenic an-
imals following heat induction. (C) Work flow describing Orsay virus reverse
genetics. IFA, immunofluorescence assay.
Jiang et al.
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Western blotting. C. elegans was infected with transgenic filtrate as
described above. The infected animals in a 6-well plate were passaged to
expand by transferring 1 cm2 of agar to a 10-cm NGM plate seeded with
OP50. Approaching starvation, infectedC. elegans animals were harvested
and homogenized. Western blotting was performed as previously de-
scribed (3). Briefly, the infected homogenates weremixedwith 6 sample
loading buffer (0.35 M Tris-HCl, 10% SDS, 0.6 M dithiothreitol [DTT],
0.012% bromphenol blue, 30% glycerol) and boiled for 5 min. Protein
samples were loaded into an 8.6-cm-long precast SDS-PAGE gel (Any kD
Mini-PROTEANTGX gel; Bio-Rad), and the gel was run at 30mA for 1 h.
Proteins were transferred to a polyvinylidene difluoride (PVDF) mem-
brane (Invitrogen) and blotted with specific viral capsid peptide-derived
antibody.
Immunofluorescence assay. (i) Epifluorescence analysis of rec-WT
and nat-WT infection (see Fig. 2). Immunofluorescence staining for Or-
say virus capsid was performed as described before (33). The initial re-
combinantwild typeOrsay virus (rec-WT)-infected and the naturalOrsay
virus (nat-WT)-infected rde-1 animals were passaged by transfer from a
6-well NGM plate to a 10-cm OP50-seeded NGM plate. After 4 days, the
infected C. elegans animals were fixed in Bouin’s fixative and quickly fro-
zen in liquid nitrogen. Immunofluorescence staining was performed by
incubation with a rabbit anti-capsid primary antibody followed by Alexa
Fluor 488-labeled goat anti-rabbit secondary antibody (Invitrogen). Im-
ages for epifluorescence were acquired with a Zeiss Axioskop Mot Plus
fluorescence microscope.
(ii) Confocal microscopy of rec-FLAG and rec-WT infection (see
Fig. 4). rde-1 animals were synchronized by bleaching, and 2,000 embryos
were seeded in each well of a 6-well plate with a 20l of an OP50 bacterial
lawn. C. elegans animals were infected 16 h later with 20 l of rec-WT or
recombinant FLAG-taggedOrsay virus (rec-FLAG) virus filtrate prepared
as described above. Twenty-four hours after infection, the infected C.
elegans animals were fixed with Bouin’s fixative and frozen in liquid ni-
trogen. Double immunofluorescence staining was performed with an an-
ti-FLAGM2 monoclonal antibody (Sigma) and viral protein-specific an-
tibodies (rabbit-derived anti-capsid antibody or anti-delta antibody).
Secondary antibodies were Alexa Fluor 488-labeled goat anti-mouse an-
tibody or Alexa Fluor 568-labeled goat anti-rabbit antibody (Invitrogen).
Nuclear staining was performed with TO-PRO3 (Invitrogen) for 20 min.
Confocal images were acquired with a Zeiss LSM510 Meta laser scanning
confocal microscope (Carl Zeiss Inc., Thornwood, NY).
RESULTS AND DISCUSSION
Experimental strategy for development of Orsay virus reverse
genetics. The overall strategy for generating recombinant Orsay
virus entailed engineering plasmids that contain cDNAs of Orsay
virus RNA1 and RNA2 and then microinjecting the plasmids to-
gether to create transgenic animals harboring extrachromosomal
arrays of the two plasmids, which should then initiate host cell
transcription from the plasmids. In theory, translation of theDNA
templated transcripts would lead to expression of the Orsay virus
RdRP, which would then trigger authentic viral replication and
subsequent capsid expression and viral packaging. To evaluate the
production of viable virus, the animals were then homogenized
and filtered through a 0.22-m membrane; the resulting filtrate
was then used for de novo infection of naive animals and subse-
quently assayed by qRT-PCR, Western blotting, or immunofluo-
rescence assay (Fig. 1).
Specifically, cDNA sequences of the Orsay virus RNA1 and











































FIG 2 De novo infection of C. elegans by virus produced from transgenic animals. (A) Real-time qRT-PCR quantification of both recombinant wild-type Orsay
virus (rec-WT) and naturally occurring Orsay virus (nat-WT) replication inC. elegansN2 and rde-1 strains. A nontransgenicC. elegansN2 preparation was used
as amock control.N/D, viral RNAwas not detected. Error bars indicate standard deviations from three independent infection experiments. (B)Western blotwith
anti-Orsay virus capsid antibody. Arrow indicates the virus capsid band. (C) Immunofluorescence staining of recombinant and natural Orsay virus replication
in infected C. elegans with anti-Orsay virus capsid antibody. Arrows indicate the infected intestinal cells. Scale bars represent 20 m.








rec-WT1 N2 3 1
rec-WT2 N2 4 3
rec-MUT N2 7 3
rec-FLAG rde-1 5 1
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heat-inducible promoter. One reason we chose this promoter is
that it is known to be preferentially active in the C. elegans pha-
ryngeal and intestinal tissue (30), which coincides with the Orsay
virus in vivo tissue tropism (33). Prior studies that developed cell
culture-based reverse genetics systems for influenza A virus and
Pariacoto virus, an insect nodavirus, demonstrated the strict re-
quirement for maintaining authentic termini of the genome seg-
ments for optimal viral replication (10, 11, 16). Therefore, we
introduced a hepatitis D virus ribozyme at the 3= end of the RNA1
segment, and at the 5= end, the Orsay virus cDNA was cloned
immediately 3= to the heat-inducible promoter transcriptional
start site (Fig. 1A). The transcript produced from this construct
following ribozyme cleavage should, in theory, be identical in se-
quence to authentic Orsay virus genomic RNAs.
Wild-type Orsay virus produced from transgenic C. elegans
is infectious. To demonstrate that the transgenic C. elegans re-
verse genetics system works in principle, we focused first on
generating recombinant wild-type Orsay virus. Plasmids
pHIP_RNA1 and pHIP_RNA2 were microinjected along with
pRF4, a “roller” phenotypic marker plasmid, and three stable F2
transgenic animals were identified by screening for the roller phe-
notype. The stable transgenic animals were then heat shocked to
induce the expression of Orsay virus RNA. Two days post-heat
shock, expression of both Orsay virus RNA1 and RNA2 was de-
tected by real-time qRT-PCR in all three lines (data not shown).
Virus filtrates were generated from each of these lines, and
following infection of N2 and rde-1 strains ofC. elegans, one of the
three filtrates yielded viable virus that behaved as natural Orsay
virus (nat-WT). By qRT-PCR, the recombinant wild-type Orsay
virus (rec-WT) produced from transgenic animals replicated to
higher levels in the RNAi-deficient C. elegans rde-1 strain than in
the N2 strain, as seen with natural nat-WT infection (Fig. 2A).
Patterns of viral capsid protein expression as assessed by both
Western blotting (Fig. 2B) and immunofluorescence assay (Fig.
2C)were similar for both natural and recombinantOrsay virus. In
a second independent experiment, three out of four stable trans-
genic strains that we generated produced recombinant wild-type
Orsay virus (Table 2). Overall, the process of microinjection and
identification of progeny producing virus requires about 15 days.
To evaluate the stability of virus production in the transgenic
C. elegans harboring pHIP_RNA1 and pHIP_RNA2, we con-
ducted 7 serial passages of the transgenic strain. Filtrates generated
following heat induction of passages 5, 6, and 7 each contained
viable virus as defined by de novo infection and qRT-PCR (see Fig.
S2A in the supplemental material). In addition, an aliquot of the
F4 that had been frozen in a80°C freezer, upon revival and heat
shock of its F5 progeny, also yielded viable virus (see Fig. S2A).
These results demonstrate the generation of recombinant wild-
type Orsay virus through a plasmid-based reverse genetics system
in the metazoan host C. elegans and the stability of the transgenic
strains.
Ageneticmarker canbe introduced intoOrsay virus genome
by reverse genetics.Wenext created a plasmid containing a series
of three synonymous point mutations that were in the wobble
position of three consecutive codons (pHIP-RNA1MUT) in the
middle of the Orsay virus RdRP to demonstrate that recombinant
viruses with defined mutations could be generated (Fig. 3A).
Transgenic C. elegans strains were created by microinjecting
pHIP_RNA1MUT and pHIP_RNA2, and viral filtrates were pre-
pared as before. Infection of the rde-1 strain with mutant viruses
(rec-MUT1, rec-MUT2, and rec-MUT3) produced from three in-
dependent transgenic strains showed levels of replication similar
to that with rec-WT infection in the rde-1 strain (data not shown).
Confirming that these viruses were recombinant in origin, RT-
PCR of RNA extracted from the de novo-infected rde-1 C. elegans
generated the expected band (Fig. 3B), and sequencing of the am-
plicon yielded the three synonymous mutations (Fig. 3C). As a
1.......10........20........30.....
Amino acid: G-586L-587D





















































FIG 3 Introduction of a genetic marker into the Orsay virus genome. (A)
Design of an Orsay virus genetic marker in its RNA1 genome segment. Arrows
indicate the position where primers were used to perform RT-PCR. Letters in
green highlight the three synonymous pointmutations introduced, with aster-
isks indicating their positions in the genome. (B) RT-PCR and PCR spanning
the mutated locus. RNA was extracted from three C. elegans cultures infected
by three independent mutant virus filtrates. The expected PCR band is600
bp. M, molecular size marker. (C) The genetic marker was preserved in the
recombinant virus as shown by the Sanger sequencing chromatogram of the
three mutant viruses. Aligned boxes indicate the genetic marker.
Jiang et al.
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control, PCR amplification in the absence of RT yielded no bands
(Fig. 3B), eliminating any possibility of residual carryover of
pHIP_RNA1MUT plasmid from the transgenic animal filtrate
(Fig. 3B). Furthermore, serial passage of the rec-MUT virus-in-
fected animals showed the presence of the three synonymousmu-
tations in the recombinant virus genome at the third passage by
sequencing (data not shown). These results clearly demonstrate
the ability to generate mutants in the Orsay virus genome using
this plasmid-based reverse genetics system.
Generation of a FLAG epitope-tagged Orsay virus by re-
verse genetics. To further demonstrate the feasibility of genetic
engineering of Orsay virus, we next created a plasmid
(pHIP_RNA2FLAG) that encoded an epitope tag (FLAG: DYKD
DDDK) with a 5-amino-acid linker sequence, SGAAA (Fig. 4A).
We have previously demonstrated that the Orsay virus RNA2 seg-
ment encodes the capsid protein (alpha) and an alpha-delta fusion
protein of unknown function that is expressed by a ribosomal
frameshiftingmechanism (3). Thus, the FLAG tagwas designed to
be expressed at the C terminus of the alpha-delta fusion protein
(Fig. 4A). Following generation of transgenic animals and virus
filtrate preparation, de novo infection of rde-1 C. elegans demon-
strated replication of the FLAG-tagged Orsay virus (data not
shown). RT-PCR primers that span the FLAG sequence insertion
site were designed. A band with higher molecular weight was ob-
tained with RNA extracted from rec-FLAG-infected animals than















































5’NC RZpHIP 3’NCRNA2 ORF
FIG 4 Generation and verification of a FLAG epitope-tagged Orsay virus. (A) A schematic design of FLAG-tagged Orsay virus RNA2 genome segment.
Both the genome construct and expected proteins are shown. The nucleotide and amino acid sequences of FLAG peptide tag are underlined, and those for
the linker peptide are italicized. #, stop codon. (B) RT-PCR and direct PCR were performed on the FLAG-tagged virus-infected C. elegans. (C) Double
immunofluorescence staining of rec-WT-infected C. elegans with anti-Orsay capsid and anti-Orsay delta peptide antibodies. Scale bars represent 10 m. (D)
Double immunofluorescence staining of rec-FLAG- and rec-WT-infected C. elegans with anti-Orsay capsid peptide antibody and monoclonal anti-FLAG
antibody. (E) Double immunofluorescence staining of rec-FLAG- and rec-WT-infected C. elegans with anti-Orsay delta peptide antibody and monoclonal
anti-FLAG antibody.
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(Fig. 4B, compare lane 3 to lane 4). No bands were obtained from
either sample in the absence of reverse transcription. The presence
of the FLAG sequence was confirmed by Sanger sequencing of the
RT-PCR amplicon (data not shown).
To evaluate the expression of the FLAG epitope, the rec-FLAG
virus was used to infect the rde-1 strain. We have previously re-
ported that infection byOrsay virus primarily leads to a detectable
level of viral capsid protein in one or more intestinal cells (33).
More recently, we determined that the delta protein is expressed
primarily as a fusion with the capsid protein (3). Double immu-
nofluorescence staining with antibodies raised against peptides
from the capsid and delta regions led to costaining of the same
cells with the same subcellular patterns (Fig. 4C). Thus, we antic-
ipated that double staining of animals infected by rec-FLAG with
anti-FLAG and either anti-capsid or anti-delta should similarly
colocalize. As expected, staining with both anti-FLAG monoclo-
nal antibody and the anti-Orsay capsid antibody of rec-FLAG-
infected animals yielded colocalization of the capsid and FLAG
peptide within the same intestinal cells (Fig. 4D). In addition,
similar results were obtained when rec-FLAG-infected animals
were costained with anti-FLAG antibody and an anti-delta pep-
tide antibody (Fig. 4E). In each case, double staining of animals
infectedwith rec-WTyielded only capsid or delta protein staining;
no FLAG staining was observed. Based on these results, we con-
clude that it is possible to use this reverse genetics system to create
recombinant forms of Orsay virus that express mutant or tagged
proteins.
Because the presence of the FLAG epitope physically alters the
alpha-delta fusion protein, we assessed the stability of the rec-
FLAG virus. Infected animals were serially propagated by transfer
every 4 days for 6 passages. At each passage, RNA was extracted
and RT-PCR using primers flanking the FLAG insertion con-
firmed the presence of the FLAG coding sequence. No evidence of
loss of the FLAG sequence or reversion to wild type was observed
during this time frame (see Fig. S2B in the supplemental material;
other data not shown).
In summary, we have demonstrated the feasibility of using a
transgenic C. elegans-based reverse genetics system to generate
recombinant mutants of Orsay virus. This capability will open
new frontiers of viral research in C. elegans. In theory, it should
now be possible to create fluorescent versions Orsay virus, for
example, by fusion of green fluorescent protein (GFP) or intro-
duction of a fluorescent RNA aptamer (34) that could be used to
visualize and follow infection in live animals. Such a virus would
also be ideal as a reporter for high-throughput functional screens
of host genes that affect Orsay virus infectivity and replication. Of
course, as with all reverse genetics systems, there are likely to be
constraints on the size of the insertion that can be tolerated at both
the genome and protein levels. Structural studies of the Orsay
capsid and capsid-delta fusion would be helpful in providing in-
sight into sites thatmay bemore amenable tomanipulation.Other
applications of this system in the future could include efforts to
make viruses that cannot express the capsid-delta fusion protein
to facilitate efforts to define the function of this mysterious pro-
tein. Furthermore, by choosing tissue-specific promoters for ini-
tial expression constructs, it may also be possible to direct Orsay
virus expression to specific tissues, as has recently been described
for Drosophila with modified Sindbis virus (28). The successful
development ofOrsay virus reverse genetics also provides the pos-
sibility of generating similar systems for the other twoCaenorhab-
ditis nematode-infecting viruses, Le Blanc and Santeuil viruses
(2). As both of those viruses have the opposite host specificity of
Orsay virus (i.e., they can infectCaenorhabditis briggsae but notC.
elegans), the availability of reverse genetics would enable the cre-
ation of reassortant or chimeric viruses that could then be used to
explore viral and host factors that govern infection specificity. To
conclude, theOrsay virus reverse genetics systemdeveloped in this
work will greatly facilitate studies of Orsay virus and its interac-
tions with its host, C. elegans.
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